MEKOPHAR CHEMICAL PHARMACEUTICAL JOINT-STOCK COMPANY

Reviewed Interim financial statements
for the six-month period ended 30 June 2026

CONTENTS

14896
NG
NHH
M TO
VIỆT
HỒ

THE BOARD OF DIRECTORS' REPORT

The Board of Directors of Mekophar Chemical Pharmaceutical Joint-Stock Company (briefly called "the Company") has the pleasure in presenting this report and the Reviewed Interim financial statements of the Company for the six-month period ended 30 June 2026.

1. General information

Mekophar Chemical Pharmaceutical Joint-Stock Company is operating under the Business Registration Certificate No. 0302533156 on 08 February 2002 issued by the Department of Planning and Investment of Ho Chi Minh City, and the 23th amendment Business Registration Certificate dated 18 July 2025.

Charter capital of the Company at 30/06/2026 and at 01/01/2026 is VND 255,458,670,000 equivalent with 25,545,867 shares which have par value of VND 10,000/ share.

The Company's shares are officially traded on the UPCOM market - the stock exchange of unlisted public companies on the Hanoi Stock Exchange with the stock code MKP according to Decision No. 1072/QD-SGDHN issued by Hanoi Stock Exchange on 29 December 2017 and the first trading date was 29 January 2018.

The Company's head office is located at 297/5 Ly Thuong Kiet Street, Phu Tho Ward, Ho Chi Minh City, Vietnam.

According to Business registration certificate, the Company's business activities are:

- Producing medicine, pharmaceutical chemicals and medical substances;
- Producing other foodstuffs not yet classified in any other category;
- Producing non-alcoholic beverages and mineral water;
- Producing wooden crates for packaging;
- Short-time accommodation;
- Other uncategorized specialized wholesale;
- Retail of medication, medical equipment, cosmetic, hygiene products in specialized stores;
- Wholesale of food products;
- Wholesale of beverages;
- Wholesale of other household uncategorized appliances;
- Wholesale of other machines, equipment and spare parts;
- Commercial introduction and promotion;
- Other uncategorized financial services;
- Doing business in real-estate, land use rights of owner, users or leased land;
- Technical inspection and analysis;
- Other professional practice, science and technology;
- Agency, intermediary, auction;
- Wholesale of cloth, garments and footwear;
- Activities of hospitals, health stations;
- Other medical activities not classified in any category;
- Producing cosmetics, soap, detergent, polish and sanitary finished product;
- Medical and dental practice activities.

In this period, the Company's principal activities are producing medicine, pharmaceutical chemicals and medical substances.

2. The members of Board of Directors, Board of General Directors and Board of Supervisors

The members of the Board of Directors, the Board of General Directors and the Board of Supervisors in the six-month period ended 30 June 2026 and to the date of this report include:

The Board of Directors

Full name	Position	
Mr. Le Anh Phuong	Chairman	Appointed on 24/04/2025
Ms. Huynh Thi Lan	Vice Chairman	Appointed on 24/04/2025
Ms. Dang Thi Kim Lan	Member	Appointed on 24/04/2025
Ms. Phan Thi Lan Huong	Member	Appointed on 24/04/2025
Ms. Nguyen Thi Hang	Non-executive Member	Appointed on 24/04/2025

THE BOARD OF DIRECTORS' REPORT

The Board of General Directors and Chief Accountant

Full name	**Position**	
Ms. Phan Thi Lan Huong	General Director	Appointed on 07/05/2025
Ms. Huynh Thi Lan	Deputy General Director	Appointed on 07/05/2025
Mr. Le Anh Phuong	Deputy General Director	Appointed on 01/10/2010
Mr. Phan Anh Tai	Chief Accountant	Appointed on 01/06/2021

The Board of Supervisors

Full name	**Position**	Appointed on 24/04/2025
Mr. Nguyen Viet Luan	Chief Supervisor	Appointed on 24/04/2025
Mr. Nguyen Ba Khoa	Member	Appointed on 24/04/2025
Mr. Tran Trung Ngon	Member	Appointed on 24/04/2025

Legal Representative

The Legal Representative of the Company during the six-month period ended at 30 June 2026 and at the date of this report is:

Full name	**Nationality**	**Position**
Ms. Phan Thi Lan Huong	Vietnamese	General Director

3. The Company's financial position and operating results

The Company's financial position and its operating result for the six-month period ended 30 June 2026 are reflected in the accompanying interim financial statements.

4. Events subsequent to the financial position statement date

There have been no significant events occurring after the financial position statement date which would require adjustments or disclosures to be made in the Notes to the interim Financial statements

5. Auditors

AFC Vietnam Auditing Company Limited has been appointed to review the Company's interim financial statements for the six-month period ended 30 June 2026.

6. Statement of the Board of General Directors' responsibility in respect of the interim financial statements

The Board of General Directors of the Company is responsible for preparing the interim financial statements which give a true and fair view of the financial position of the Company, as well as of its operation results and its cash flows for the six-month period ended 30 June 2026. In preparing those interim financial statements, the Board of General Directors is required to:

- Select suitable accounting policies and then apply them consistently;
- Make judgments and estimates that are reasonable and prudent;
- State whether applicable accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements;
- Prepare the financial statements on the going concern basic unless it is inappropriate to presume that the Company will continue in business; and
- Design, implement and maintain the Company's internal control for prevention and detection of fraud and error to preparation and presentation of the financial statements.

THE BOARD OF DIRECTORS' REPORT

The Board of General Directors is responsible for ensuring that the proper accounting records are kept which disclose, with reasonable accuracy at any time, the financial position of the Company and to ensure that the accounting records comply with the Vietnamese Accounting System. The Board of General Directors is also responsible for managing the assets of the Company and therefore has taken the appropriate measures to prevent and detect frauds and other irregularities.

The Board of General Directors confirmed that the Company has complied with the above requirements in preparing the accompanying interim financial statements.

7. Approval of the interim financial statements

The Board of Directors hereby approves the accompanying financial statements which give a true and fair view of the financial position of the Company as at 30 June 2026, its operation results and cash flows of the Company for the six-month period ended 30 June 2026 in accordance with the Vietnamese Accounting Standards, Vietnamese Accounting System and comply with relevant statutory requirements relating to the preparation and presentation of interim financial statements.

On behalf of the Board of Directors

M.S.D.N: 0302533156-C.T.C.P
CÔNG TY
CỔ PHẦN
HÓA-DƯỢC PHẨM
MEKOPHAR
THÀNH PHỐ HỒ CHÍ MINH

LE ANH PHUONG
Chairman
Approved, 14 August 2026

Công ty TNHH Kiểm Toán AFC Việt Nam
AFC Vietnam Auditing Co., Ltd.
Thành viên tập đoàn PKF Quốc tế
Member firm of PKF International

PKF

No: 222/2026/BCSX-HCM.01387

REPORT ON REVIEW OF INTERIM FINANCIAL STATEMENTS

To: **The Shareholders, the Board of Directors and the Board of General Directors Mekophar Chemical Pharmaceutical Joint-Stock Company**

We have reviewed the accompanying interim financial statements of Mekophar Chemical Pharmaceutical Joint-Stock Company ("the Company"), prepared on 14 August 2026, as set out from page 5 to 38, which comprise the Interim Financial position statement as at 30 June 2026, the Interim Income statement, the Interim Cash flow statement for the six-month period ended 30 June 2026 and the Notes to the Interim Financial statements.

The Board of General Directors' responsibility

The Board of General Directors of the Company is responsible for the preparation and fair presentation of these interim financial statements of the Company in accordance with the Vietnamese Accounting Standards, Vietnamese Accounting System and comply with relevant statutory requirements to preparation and presentation of the financial statements and for such internal control as the Board of General Directors of the Company determines is necessary to enable the preparation and presentation of these interim financial statements that are free from material misstatement, whether due to fraud or error.

Auditor's responsibility

Our responsibility is to express a conclusion these interim financial statements based on our review. We conducted our review in accordance with Vietnamese Standards on Review Engagements No. 2410 - Review of Interim Financial Information Performed by the Independent Auditor of the Entity.

A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Vietnamese Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Auditor's Conclusion

Based on our review, nothing has come to our attention that causes us to believe that the accompanying interim financial statements do not give a true and fair view, in all material respects, of the interim financial position of Mekophar Chemical Pharmaceutical Joint-Stock Company as at 30 June 2026, and of the interim income statement and their interim cash flows for the six-month period then ended in accordance with Vietnamese Accounting Standards, Vietnamese Accounting System, and the statutory requirements relevant to the preparation and presentation of interim financial statements.

PHAM THI NGOC LIEN	**LE HUYNH BAO**
Deputy General Director	**Auditor**
Audit Practicing Registration Certificate	Audit Practicing Registration Certificate
No. 1180-2023-009-1	No. 5449-2026-009-1
Authorized representative	

AFC VIETNAM AUDITING COMPANY LIMITED
Ho Chi Minh City, 14 August 2026

Ho Chi Minh City Head Office • Tel: +84 28 2220 0237 • Fax: +84 28 2220 0265 • Email: pkf.afchcm@pkf.afcvietnam.vn
2/F Indochina Park Tower • No. 4 Nguyen Dinh Chieu Street • Tan Dinh Ward • Ho Chi Minh City • Vietnam • Website: www.pkf.afcvietnam.vn

PKF AFC Vietnam Auditing Co., Ltd. is a member of PKF Global, the network of member firms of PKF International Limited, each of which is a separate and independent legal entity and does not accept any responsibility or liability for the actions or inactions of any individual member or correspondent firm(s).

INTERIM FINANCIAL POSITION STATEMENT

As at 30 June 2026

ITEMS	Code	Notes	30/06/2026 VND	01/01/2026 VND
ASSETS				
A - CURRENT ASSETS	**100**		**988,957,807,594**	**1,030,851,301,463**
I. Cash and cash equivalents	**110**	5.1	**33,383,400,651**	**228,274,668,339**
1. Cash	111		18,371,688,321	20,124,264,229
2. Cash equivalents	112		15,011,712,330	208,150,404,110
II. Short-term financial investments	**120**	5.2	**216,534,867,265**	**32,372,179,593**
1. Trading securities	121		6,876,711,100	6,876,711,100
2. Provision for impairment of trading securities	122		-	-
3. Held-to-maturity investments	123		209,658,156,165	25,495,468,493
4. Provision for short-term held-to-maturity investments	124		-	-
5. Other short-term investments	125		-	-
6. Provision for diminution in value of other short-term investments	126		-	-
III. Short-term receivables	**130**		**66,148,835,546**	**114,685,716,096**
1. Short-term trade receivables	131	5.3	54,870,834,467	57,914,728,301
2. Short-term advances to suppliers	132	5.4	12,046,685,820	25,763,944,068
3. Short-term inter-company receivables	133		-	-
4. Receivable due according to the construction contract schedule	134		-	-
5. Other short-term receivables	135	5.5	11,036,577,783	42,814,071,316
6. Provision for short-term doubtful debts	136	5.6	(11,805,262,524)	(11,807,027,589)
7. Deficient assets pending resolution	137		-	-
IV. Inventories	**140**	5.7	**644,515,761,116**	**640,537,350,817**
1. Inventories	141		674,858,654,977	670,880,244,678
2. Provision for devaluation in inventories	142		(30,342,893,861)	(30,342,893,861)
V. Short-term biological assets	**150**		**-**	**-**
1. Short-term raising livestock for one-time harvest	151		-	-
2. Short-term seasonal or one-time harvest crops	152		-	-
3. Provision for short-term biological asset losses	153		-	-
VI. Other short-term assets	**160**		**28,374,943,016**	**14,981,386,618**
1. Short-term deferred expenses	161	5.8	3,905,518,480	3,712,847,687
2. VAT deductible	162		11,015,106,361	9,604,778,503
3. Taxes and other receivables from State budget	163	5.15	13,454,318,175	1,663,760,428
4. Transactions to buy, resell government bonds	164		-	-
5. Other short-term assets	165		-	-

INTERIM FINANCIAL POSITION STATEMENT

As at 30 June 2026

ITEMS	Code	Notes	30/06/2026 VND	01/01/2026 VND
B - NON-CURRENT ASSETS	**200**		**632,924,036,679**	**628,433,488,227**
I. Long-term receivables	**210**		**81,100,800**	**-**
1. Long-term trade receivables	211		-	-
2. Long-term advances to suppliers	212		-	-
3. Paid-in capital in wholly-owned subsidiaries	213		-	-
4. Long-term inter-company receivables	214		-	-
5. Other long-term receivables	215	5.5	81,100,800	-
6. Provision for doubtful long-term debts	216		-	-
II. Fixed assets	**220**		**597,502,187,992**	**602,292,259,051**
1. Tangible fixed assets	221	5.9	589,784,059,309	594,521,695,372
- Cost	222		1,054,853,929,598	1,040,867,544,798
- Accumulated depreciation	223		(465,069,870,289)	(446,345,849,426)
2. Finance leases	224		-	-
- Cost	225		-	-
- Accumulated depreciation	226		-	-
3. Intangible fixed assets	227	5.10	7,718,128,683	7,770,563,679
- Cost	228		14,004,583,139	14,004,583,139
- Accumulated amortization	229		(6,286,454,456)	(6,234,019,460)
III. Long-term biological assets	**230**		**-**	**-**
1. Long-term raising livestock for periodic production	231		-	-
a) Livestock raised for periodic production have not yet reached maturity	232		-	-
b) Livestock raised for periodic production have reached maturity	233		-	-
- Cost	234		-	-
- Accumulated amortization	235		-	-
2. Long-term raising livestock for one-time harvest	236		-	-
3. Long-term seasonal or one-time harvest crops	237		-	-
4. Provision for Long-term biological asset losses	238		-	-
IV. Investment property	**240**		**-**	**-**
- Cost	241		-	-
- Accumulated depreciation	242		-	-
V. Long-term assets in progress	**250**		**9,553,733,333**	**80,571,727**
1. Long-term work in progress	251		-	-
2. Construction in progress	252	5.11	9,553,733,333	80,571,727
VI. Long-term financial investments	**260**		**24,068,960,000**	**24,068,960,000**
1. Investments in subsidiaries	261		-	-
2. Investment in Joint-venture and associates	262		-	-
3. Investments in other entities	263	5.2	24,068,960,000	24,068,960,000
4. Provision for diminution in value of long-term investments in other entities	264		-	-
5. Held-to-maturity investment	265		-	-
6. Provision for Long-term held-to-maturity investments	266		-	-
VII. Other non-current assets	**270**		**1,718,054,554**	**1,991,697,449**
1. Long-term deferred expenses	271	5.8	1,718,054,554	1,991,697,449
2. Deferred tax assets	272		-	-
3. Long-term equipment, supplies and spare parts	273		-	-
4. Other non-current assets	274		-	-
TOTAL ASSETS	**280**		**1,621,881,844,273**	**1,659,284,789,690**

INTERIM FINANCIAL POSITION STATEMENT

As at 30 June 2026

ITEMS	Code	Notes	30/06/2026 VND	01/01/2026 VND
RESOURCES				
C - LIABILITIES	**300**		**365,299,598,804**	**389,801,901,836**
I. Current liabilities	**310**		**158,849,678,813**	**187,912,798,591**
1. Trade accounts payable	311	5.12	56,162,930,494	95,867,307,933
2. Advance from customers	312	5.13	53,746,112,827	46,142,548,075
3. Dividends and profits payable	313	5.14	12,634,110,500	-
4. Taxes and amounts payable to State budget	314	5.15	-	-
5. Payables to employees	315		10,280,159,020	19,763,031,246
6. Accrued expenses	316	5.16	10,332,242,567	9,313,695,118
7. Inter-company payables	317		-	-
8. Payables according to the construction contract schedule	318		-	-
9. Revenue pending short-term allocation	319		-	-
10. Other current payables	320	5.17	11,071,203,118	11,134,652,329
11. Short-term borrowings and finance lease liabilities	321		-	-
12. Provision for short-term payables	322		-	-
13. Bonus and welfare funds	323	5.18	4,622,920,287	5,691,563,890
14. Price Stabilization Fund	324		-	-
15. Transactions to buy, resell government bonds	325		-	-
II. Long-term liabilities	**330**		**206,449,919,991**	**201,889,103,245**
1. Long-term trade payables	331		-	-
2. Long-term advance from customers	332		-	-
3. Taxes and amounts payable to State budget in long-term	333		-	-
4. Long-term accrued expenses	334		-	-
5. Long-term inter-company payables of capital	335		-	-
6. Long-term inter-company payables	336		-	-
7. Revenue pending long-term allocation	337	5.19	206,449,919,991	201,889,103,245
8. Other long-term liabilities	338		-	-
9. Long-term borrowings and finance lease obligations	339		-	-
10. Convertible bond	340		-	-
11. Preferred stock	341		-	-
12. Deferred income tax liabilities	342		-	-
13. Other long-term provisions	343		-	-
14. Scientific and technological development fund	344		-	-

INTERIM FINANCIAL POSITION STATEMENT

As at 30 June 2026

ITEMS	Code	Notes	30/06/2026 VND	01/01/2026 VND
D - EQUITY	**400**	5.20	**1,256,582,245,469**	**1,269,482,887,854**
1. Chartered capital	411		255,458,670,000	255,458,670,000
- Ordinary shares with voting rights	411a		255,458,670,000	255,458,670,000
- Preferred shares	411b		-	-
2. Share premium	412		409,789,114,458	409,789,114,458
3. Convertible bonds option	413		-	-
4. Other owner's capital	414		-	-
5. Treasury shares (*)	415		(14,487,151,158)	(14,487,151,158)
6. Assets revaluation difference	416		-	-
7. Foreign exchange difference	417		-	-
8. Investment and development funds	418		582,173,952,404	581,829,844,305
9. Other owner's funds	419		-	-
10. Undistributed profit after tax	420		23,647,659,765	36,892,410,249
- Undistributed profit after tax brought forward	420a		23,225,975,453	32,591,059,015
- Undistributed profit after tax for the current period	420b		421,684,312	4,301,351,234
TOTAL RESOURCES	**440**		**1,621,881,844,273**	**1,659,284,789,690**

CÔNG TY CỔ PHẦN HÓA-DƯỢC PHẨM MEKOPHAR
M.S.D.N: 0302533156 - C.T.C.P - THÀNH PHỐ HỒ CHÍ MINH

LE THI THU HUONG	PHAN ANH TAI	PHAN THI LAN HUONG
Preparer	**Chief Accountant**	**General Director**
		Legal representative
		Approved, 14 August 2026

INTERIM INCOME STATEMENT

For the six-month period ended 30 June 2026

ITEMS	Code	Notes	From 01/01/2026 to 30/06/2026 VND	From 01/01/2026 to 30/06/2026 VND
1. Revenues from sale of goods and rendering of services	01		**411,830,593,839**	**420,940,117,173**
2. Less deductions	02		41,497,128	92,845,934
3. Net revenue from sale of goods and rendering of services (10 = 01 - 02)	10	6.1	**411,789,096,711**	**420,847,271,239**
4. Cost of goods sold	11	6.2	293,892,463,050	304,811,946,283
5. Gross profit from sale of goods and rendering of services (20 = 10 - 11)	20		**117,896,633,661**	**116,035,324,956**
6. Gain/ loss from disposal of investment property	21		-	-
7. Financial income	22	6.3	6,849,904,257	2,842,958,080
8. Financial expenses	23	6.4	925,060,981	25,319,511,733
- In which: Interest expenses	24		-	-
9. Selling expenses	25	6.5	53,521,524,590	56,362,816,689
10. General and administration expenses	26	6.6	69,590,082,323	66,989,994,253
11. Operating profit {30 = 20 +21 + 22 - (23 + 25 + 26)}	30		**709,870,024**	**(29,794,039,639)**
12. Other income	31	6.7	8,323,285	359,678,156
13. Other expenses	32	6.8	148,320,508	49,678,102
14. Other profit (40 = 31 - 32)	40		**(139,997,223)**	**310,000,054**
15. Accounting profit before tax (50 = 30 + 40)	50		**569,872,801**	**(29,484,039,585)**
16. Current corporate income tax expense	51	5.15	148,188,489	-
17. Deferred corporate income tax expense	52		-	-
18. Net profit after tax (60 = 50 - 51 - 52)	60		**421,684,312**	**(29,484,039,585)**
19. Earnings per share	70	6.9	**17**	**(1,167)**

M.S.D.N:0302533156-C.T.C.P CÔNG TY CỔ PHẦN HÓA-DƯỢC PHẨM MEKOPHAR THÀNH PHỐ HỒ CHÍ MINH

LE THI THU HUONG	**PHAN ANH TAI**	**PHAN THI LAN HUONG**
Preparer	**Chief Accountant**	**General Director**
		Legal representative
		Approved, 14 August 2026

INTERIM CASH FLOW STATEMENT

(Indirect method)
For the six-month period ended 30 June 2026

ITEMS	Code	From 01/01/2026 to 30/06/2026 VND	From 01/01/2026 to 30/06/2026 VND
I. CASH FLOW FROM OPERATING ACTIVITIES			
1. Net profit before tax	01	**569,872,801**	**(29,484,039,585)**
2. Adjustments for			
- Depreciation and amortisation of fixed assets, investment property	02	18,806,780,859	4,620,733,244
- Provisions, (reversal)	03	(1,765,065)	23,639,396,406
- Gain, loss foreign exchange rate differences upon revaluation of monetary items	04	110,688,441	158,649,585
- Gain, loss from investing activities	05	(6,730,598,453)	(2,603,154,932)
- Interest expense	06	-	-
- Other adjustments	07	-	-
3. Operating profit before movements in working capital	08	**12,754,978,583**	**(3,668,415,282)**
- Increase, decrease in receivables	09	4,116,395,665	4,100,275,753
- Increase, decrease in inventories	10	(3,978,410,299)	(33,209,068,738)
- Increase, decrease in account payable (Other than interest payables, CIT payables)	11	(29,102,144,305)	(26,856,478,139)
- Increase, decrease in deferred expenses	12	80,972,102	2,268,683,213
- Increase, decrease in trading securities	13	-	-
- Interest paid	14	-	-
- Corporate income tax paid	15	(7,037,039,273)	(9,346,477,406)
- Other cash inflows	16	-	-
- Other cash outflows	17	(1,756,859,800)	(10,639,633,000)
Net cash flow from operating activities	20	**(24,922,107,327)**	**(77,351,113,599)**
II. CASH FLOW FROM INVESTING ACTIVITIES			
1. Cash outflow for purchasing and construction of fixed assets and other long-term assets	21	(23,691,461,406)	(2,800,421,455)
2. Proceeds from disposal of fixed assets and other long-term assets	22	-	22,727,273
3. Cash outflow for buying debt instruments of other entities	23	(239,000,000,000)	(177,733,726,033)
4. Cash recovered from lending, selling debt instruments of other companies	24	57,000,000,000	192,233,726,033
5. Investment in other entities	25	-	-
6. Cash recovered from investments in other entities	26	-	-
7. Interest income received, dividends received	27	35,719,260,945	2,801,715,330
Net cash flow from investing activities	30	**(169,972,200,461)**	**14,524,021,148**
III. CASH FLOW FROM FINANCIAL ACTIVITIES			
1. Proceeds from issuing stocks, receiving capital from owners	31	-	-
2. Capital withdrawals, buying treasury shares	32	-	-
3. Proceeds from short-term borrowings	33	-	-
4. Repayment of borrowings	34	-	-
5. Repayment of obligations under finance lease	35	-	-
6. Dividends paid	36	-	(12,634,110,500)
Net cash flow from financing activities	40	**-**	**(12,634,110,500)**

INTERIM CASH FLOW STATEMENT

(Indirect method)
For the six-month period ended 30 June 2026

ITEMS	Code	From 01/01/2026 to 30/06/2026 VND	From 01/01/2026 to 30/06/2026 VND
NET INCREASE/ DECREASE IN CASH IN PERIOD (50 = 20 + 30 + 40)	**50**	**(194,894,307,788)**	**(75,461,202,951)**
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD	**60**	**228,274,668,339**	**146,963,151,214**
Effects of changes in foreign exchange rate	61	3,040,100	9,809,959
CASH AND CASH EQUIVALENTS AT THE END OF PERIOD (70 = 50 + 60 + 61)	**70**	**33,383,400,651**	**71,511,758,222**

CÔNG TY CỔ PHẦN HÓA-DƯỢC PHẨM MEKOPHAR
M.S.D.N: 0302533156-C.T.C.P
THÀNH PHỐ HỒ CHÍ MINH

LE THI THU HUONG
Preparer

PHAN ANH TAI
Chief Accountant

PHAN THI LAN HUONG
General Director
Legal representative
Approved, 14 August 2026

NOTES TO THE INTERIM FINANCIAL STATEMENTS

For the six-month period ended 30 June 2026

These notes form an integral part of and should be read in conjunction with the accompanying financial statements.

1. BUSINESS HIGHLIGHTS

1.1 Structure of ownership

Mekophar Chemical Pharmaceutical Joint-Stock Company ("the Company") is operating under the Business Registration Certificate No. 0302533156 on 08 February 2002 issued by the Department of Planning and Investment of Ho Chi Minh City, and the 23th amendment Business Registration Certificate dated 18 July 2025.

Charter capital of the Company at 30/06/2026 and at 01/01/2026 is VND 255,458,670,000 equivalent with 25,545,867 shares which have par value of VND 10,000/ share.

The Company's shares are officially traded on the UPCOM market - the stock exchange of unlisted public companies on the Hanoi Stock Exchange with the stock code MKP according to Decision No. 1072/QD-SGDHN issued by Hanoi Stock Exchange on 29 December 2017 and the first trading date was 29 January 2018.

The Company's head office is located at 297/5 Ly Thuong Kiet Street, Phu Tho Ward, Ho Chi Minh City, Vietnam.

The Company has the following affiliated units:

No.	Name	Address
1	Branch of Mekophar Chemical Pharmaceutical Joint-Stock Company	B26-B28-TT17 Van Quan - Yen Phuc New Urban Area, Ha Dong Ward, Hanoi City, Vietnam
2	Branch of Mekophar Chemical Pharmaceutical Joint-Stock Company at Danang City	410 Nguyen Tri Phuong Street, Hoa Cuong Ward, Da Nang City, Vietnam
3	Branch of Mekophar Chemical Pharmaceutical Joint-Stock Company	17A Cach Mang Thang Tam Street, Binh Thuy Ward, Can Tho City, Vietnam
4	Branch of Mekophar Chemical Pharmaceutical Joint-Stock Company – Medicine Store 1	D9-10, 143/1 To Hien Thanh Street, Hoa Hung Ward, Ho Chi Minh City, Vietnam
5	Branch of Mekophar Chemical Pharmaceutical Joint-Stock Company	No.1, Alley 69, Yen Xuan Street, Vinh Hung Ward, Nghe An Province, Vietnam
6	Representative office of Mekophar Chemical Pharmaceutical Joint-Stock Company at Hanoi	BT-2D (16B-3) - 16, Mo Lao New Urban Area, Dai Mo Ward, Hanoi City, Vietnam

1.2 Scope of operating activities

The Company operates in the field of production, trading, rendering services.

1.3 Line of business

According to Business registration certificate, the Company's business activities are:

- Producing medicine, pharmaceutical chemicals and medical substances;
- Producing other foodstuffs not yet classified in any other category;
- Producing non-alcoholic beverages and mineral water;
- Producing wooden crates for packaging;
- Short-time accommodation;
- Other uncategorized specialized wholesale;
- Retail of medication, medical equipment, cosmetic, hygiene products in specialized stores;
- Wholesale of food products;
- Wholesale of beverages;
- Wholesale of other household uncategorized appliances;
- Wholesale of other machines, equipment and spare parts;
- Commercial introduction and promotion;
- Other uncategorized financial services;
- Doing business in real-estate, land use rights of owner, users or leased land;

- Technical inspection and analysis;
- Other professional practice, science and technology;
- Agency, intermediary, auction;
- Wholesale of cloth, garments and footwear;
- Activities of hospitals, health stations;
- Other medical activities not classified in any category;
- Producing cosmetics, soap, detergent, polish and sanitary finished product;
- Medical and dental practice activities.

In this period, the Company's principal activities are producing medicine, pharmaceutical chemicals and medical substances.

1.4 Normal business cycle

Business cycle of the Company is not exceeding 12 months.

1.5 Declaration on the comparability of information on the interim financial statements

The corresponding figures for the prior period are comparable with those of the current period. During this period, the Company adopted for the first time the Vietnamese Enterprise Accounting Regime issued under Circular No. 99/2025/TT-BTC dated 27 October 2025 of the Ministry of Finance ("Circular 99"), which replaces Circular No. 200/2014/TT-BTC dated 22 December 2014 ("Circular 200"). Accordingly, certain items in the financial statements have been reclassified and renamed in accordance with the new regulations to ensure comparability. These changes do not affect the Company's total assets, total liabilities, owners' equity, or profit after tax. Details are as follows:

FINANCIAL POSITION STATEMENT

ITEMS	Code	31/12/2025 Issued figures VND	01/01/2026 Restated figures VND	Net change VND
2. Cash equivalents	112	207,000,000,000	208,150,404,110	1,150,404,110
3. Held-to-maturity investments	123	25,000,000,000	25,495,468,493	495,468,493
5. Other short-term receivables	135	44,459,943,919	42,814,071,316	(1,645,872,603)

1.6 Employees

As at 30 June 2026, the total number of employees of the Company was 598 (31 December 2025: 605 persons).

2. ACCOUNTING YEAR AND ACCOUNTING CURRENCY

2.1 Fiscal year

The fiscal year of the Company is from January 01 to December 31 annually.

2.2 Accounting currency

The Company maintains its accounting records in Vietnamese dong (VND) due to the collect and spending are made primarily by currency VND.

3. ACCOUNTING STANDARDS AND REGULATIONS APPLICATION

3.1 Accounting Standards and regulations application

The financial statements are prepared and presented in accordance with the Corporate Accounting System issued under Circular No. 99/2025/TT-BTC dated 27 October 2025 ("Circular 99") of the Ministry of Finance guiding the method of preparing and presenting financial statements and Vietnamese Accounting Standards.

The Company has applied the Vietnamese Accounting Standards, Accounting System according to Circular 99 and other circulars guiding the implementation of accounting standards issued by the Ministry of Finance in Vietnam in relating to the preparation and presentation of financial statements.

3.2 Comply with the Vietnamese Accounting Standards and Vietnamese Accounting System

The Board of General Directors ensure that complied with the Vietnamese Accounting Standards and Vietnamese Accounting System according to the Circular 99 and as well as the guiding implementation of Accounting Standards issued by the Ministry of Finance in the preparation and presentation of financial statements.

4. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

4.1 Basis of preparation of the financial statements

The financial statements are prepared on the accrual basis (except for information relating to cash flows).

4.2 Foreign currency transactions

In this period, transactions in currencies other than VND during the fiscal year have been translated into VND at exchange rates ruling at the date of the transaction. At the end of the accounting period, the balances of assets and liabilities denominated in foreign currencies are translated into VND according to the average buying and selling exchange rates for transfers published on this day by the commercial bank where the Company regularly conducts transactions.

Foreign exchange differences arising during the year from transactions in foreign currencies are recognized in the financial income or expenses. Exchange differences arising from revaluation of monetary items denominated in foreign currencies as at the end of fiscal year after offsetting between increase and decrease difference is recognized in the financial income or expenses.

4.3 Cash and cash equivalents

Cash comprises cash on hand, cash in banks (demand deposits) and cash in transit. Cash equivalents are short-term highly liquid investments with an original maturity of three months or less which are readily convertible into known amounts of cash and which are subject to an insignificant risk of change in value at the report date.

4.4 Financial investments

Trading securities

Trading securities include stocks and bonds listed on the stock market; securities and other financial instruments held for trading purposes (including securities bought and sold for profit with a maturity of more than 12 months).

Trading securities are recorded at cost, including: Purchase price plus purchase costs (if any) such as brokerage expense, transaction expense, information provision, taxes, and banking fees. The original price of trading securities is determined according to the fair value of the payments at the time of the transaction. Trading securities are recorded at the time when investors have ownership, specifically: Listed securities are recognized at the time of order matching (T+0) and unlisted securities are recorded at the time of official ownership in accordance with the law.

Provision for devaluation in value of trading securities is made for possible loss in value when there is firm evidence of the market value of those securities held by the Company for trading purposes at the time of preparation of the financial statements.

Held-to-maturity investments

Investments are classified as held to maturity when the Company has the intention and ability to hold to maturity. Investments held to maturity include: bank deposits with a term (including treasury bills, promissory notes), bonds, the preferred shares which issued compulsory acquisition at a certain point in the future and loans held to maturity for the purpose of collecting interest periodically and other held to maturity investments.

Investments held to maturity are initially recognized at cost including purchase price and the expenses related to the purchase of investments. After initial recognition, these investments are stated at recoverable value. Interest income from investments held to maturity after the acquisition date is recognized in the Income statement on an accrual basis. Rates enjoyed before the holding is deducted from the cost of acquisition.

When there is strong evidence suggesting that part or all of the investments may not be recoverable and the damage can be measured reliably, the loss is recorded in financial expenses in the year and reduced directly to investment value.

When an investment is liquidated, the difference between the net disposal proceeds and the carrying amount is recognized as income or expense.

Investments in other entities

Investments in other entities are investments in equity instruments of another entity but the Company does not have control, joint control or significant influence over the investee.

These investments are initially recognized at cost, which includes the purchase price or capital contribution plus any directly attributable costs of the investment. The Board of Management reviews these investments to recognize any provision at the end of the accounting period.

Provisions for loss of investments in equity instruments of other entities are made as follows:

- For an investment in listed shares or the fair value of the investment is reliably determined, the provision is based on the market value of the shares.
- For investments whose fair value cannot be determined at the time of preparing financial statements, provision is made based on the investee's loss with an allowance equal to the difference between the actual contributed capital of the investee and the investor multiplied by the Company's capital contribution ratio compared to the total actual contributed capital of the parties in the other entity.

Increase or decrease in provision for diminution in value of investments in other entities have recorded at the end of the fiscal year, and is recognized in the financial expense.

4.5 Receivables

Trade and other receivables are stated at cost less provision for doubtful debts.

The classifications of receivables are trade receivables and other receivables, which complied with the following principles:

- Trade receivables reflect the nature of the receivables arising from commercial transactions with purchase - sale between the Company and an independent purchaser.
- Other receivables reflect the nature of the receivables arising from non-commercial transactions, and not to be related to the purchase – sale transactions.

The provision for doubtful debts represents the estimated loss due to non-payment arising on receivables that were outstanding at the financial position statement date. Increases and decreases to the provision balance are recognised as general and administrative expense in the Income statement

4.6 Inventories

Inventories are stated at the lower of cost and net realisable value.

Cost of inventories is determined as follows:

- Materials, goods: comprising all costs of purchase and related expenses directly incurred in bringing the inventories to their present location and condition.
- Finished goods: comprising costs of raw materials, direct labor and general production costs directly related to the production process.
- Work in process: including raw materials expenses, direct labor and production expenses.

Net realisable value means the estimated selling price of inventories in the ordinary course of business less the estimated costs of completion and the estimated costs necessary to make the sale.

Inventory value is calculated each time it is acquired, and the cost is determined on the weighted average method.

Provision for decline of inventories is made for each inventory with the cost greater than the net realisable value. Increase or decrease in the balance of provision for decline of inventories should be set aside at the fiscal year end and is recognized in cost of goods sold.

4.7 Deferred expenses

Deferred expenses are reported as short-term or long-term deferred expenses on the financial position statement and amortised over the period for which the amounts are paid or the period in which economic benefits are generated in relation to these expenses.

Deferred expenses of the Company include:

Repairing expenses, tools and equipment

Tools and equipment's has been put into use are amortised to expense under the straight-line method to amortise time not exceeding 3 years.

4.8 Tangible fixed assets

Tangible fixed assets are stated at cost less accumulated depreciation. The historical cost of tangible fixed assets include all the expenses that the Company incurs to get fixed assets by the time the asset is put into a state ready for use. Costs incurred after initial recognition is only recorded as increase in cost of fixed assets if these costs are sure to increase economic benefits in the future by using this assets. The costs incurred are not satisfied conditions are recognized as an expense in the period.

When selling or liquidating assets, their cost and accumulated depreciation of the assets are written off in the financial statements and any gain or loss which are arising from disposal are recorded in the income statement.

Depreciation of tangible fixed assets which is calculated under the straight-line depreciation method with useful time of the asset is estimated as follows:

	Years
Building and structure	05 – 45
Machinery and equipment	03 – 12
Transportation	05 – 10
Office equipment	04 – 10

4.9 Intangible fixed assets

Intangible fixed assets are stated at cost less accumulated depreciation.

The historical cost of intangible fixed assets include all the expenses that the Company incurs to get fixed assets by the time the asset is put into a state ready for use. Costs related to intangible assets incurred after initial recognition are recognized as expenses in the period, unless these costs are associated with an intangible asset and increase economic benefits from these assets.

When assets are sold or retired, their cost and accumulated depreciation are removed from the financial position statement and any gain or losses resulting from their disposal are recognized in other income or other expense.

The Company's intangible fixed assets include:

Copyright of stem cells usage

All the actual costs that the Company spent related directly to copyright of stem cells usage. The copyright of stem cells usage of the Company is amortised in 3 years.

Land use rights

Land use rights are all the actual costs that the Company spent related directly to the land use, includes: money spent to have the right to use land, compensation and site clearance expense, leveling, registration fee,... The land use right of the Company is recorded according to cost base and is not amortised.

Computer software

The expenses of purchasing computer software, which is not a part associated with the relevant hardware, will be capitalised. The initial cost of computer software includes all the expenses paid until the date the software is put into use. Computer software is amortised according to straight –line method in 2-5 years.

4.10 Construction in progress

Construction in progress presents costs that are directly related (including related interest expenses in accordance with the Company's accounting policy) to assets under construction, machinery and equipment being installed for production, leasing and management purposes as well as costs related to the repair of fixed assets in progress. These assets are stated at cost and are not depreciated.

4.11 Accounts payables and accrued expenses

Accounts payable and accrued payable are recognized for amounts to be paid in the future, which are related to the goods and services received. Accrued payables are recorded based on reasonable estimates of the amounts payable.

The classification of liabilities is trade payable, accrued expenses and other payables are in accordance with the following principles:
- Trade payables reflects the payables occurring from the commercial transactions with purchase of goods, services, property and the seller, which is an independent unit with the Company.
- Accrued payables reflect the amounts payable for goods and services received from the seller or has provided to the buyer but not paid due to no or insufficient billing records, accounting records and payable to employees on sabbatical salary, production costs that must be accrued.
- Other payables reflect the payables from non-commercial payables and not relate to the purchase – sale transactions.

4.12 Salary

Salary expenses are determined based on salary, wage and allowances as stated in agreed-upon labor contracts.

4.13 Salary deduction

Social insurance is deducted base on salary under labor contract at a cost of 17.5% and deducted from employees' salaries 8%.

Health insurance is deducted base on salary under labor contract at a cost of 3% and deducted from employees' salaries 1.5%.

Unemployment insurance is deducted base on salary under labor contract at a cost of 1% and deducted from employees' salaries 1%

Trade unions fees deducted on salaries to the cost of 2%.

4.14 Unrealized revenue

Unrealized revenue is an advance revenue mainly consisting of prepayments from customers for one or more accounting periods for asset leasing.

The Company recognizes unrealized revenue in proportion to the obligations that the Company will have to perform in the future. When the revenue recognition conditions are met, unrealized revenue is recognized in the income statement for the period corresponding to the portion that satisfies the revenue recognition condition.

4.15 Owners' equity

Contributed capital of the owner

Capital is recorded according to the amount actually invested by shareholders.

Share premium

Share premium are recognized at the difference between the issued price and face value of shares when first released, the release added, the difference between the price reissued and the book value of treasury shares and structures the capital of the convertible bond at maturity. Direct expenses related to the issuance of additional shares and treasury shares reissued are reduced Share premium.

Treasury shares

When repurchasing shares issued by the Company, the payment including transaction-related expenses is recognized as treasury shares and recorded as a deduction in equity. When re-issuing, the difference between the re-issuance price and the book price of treasury shares is recorded in the item "Share premium".

Funds

Funds are set up and used in accordance with the Company's Charter.

4.16 Profit distribution

Profit after corporate income tax is distributed to shareholders after the deduction of funds under the Charter of the Company and the provisions of the law which were approved by the General Meeting of Shareholders.

The distribution of profits to shareholders is considered non-monetary assets and liabilities in net undistributed profit may affect cash flow and ability to pay dividends as profit from revaluation of assets contributed as capital and interest due to the revaluation of monetary items, the financial instruments and non-monetary items other.

Dividends are recognized as liabilities when approved by the General Meeting of Shareholders.

4.17 Revenues

Revenues from sales of goods

Revenues from sales shall be recognized if it simultaneously meets the following five (5) conditions:

(a) The Company has transferred the majority of risks and benefits associated with the right to own the products or goods to the buyer;

(b) The Company no longer holds the right to manage the goods as the goods owner, or the right to control the goods;

(c) Revenues from sales has been determined with relative certainty. When the contract states that the buyer is entitled to return the purchased products and goods under specific conditions, the Company can only recognize revenue when those specific conditions no longer exist and the buyer is not entitled to return the product ((except for return in the form of exchange for other goods or services);

(d) The Company has gained or will gain economic benefits from the good sale transaction;

(e) It is possible to determine the costs related to the goods sale transaction.

Property rental revenue

Property rental revenue is recognized on the principle of allocating the rental amount received in advance in accordance with the rental period.

Revenues from rendering services

The revenue of transaction related to the provision of services is recorded when the result of the transaction can be measured reliably. In case that the services are to be provided in many accounting periods, the determination of sales in each period is done on the basis of the service completion rate as of the financial position statement date. The result of this transaction can be measured reliably when satisfy all four conditions:

(a) Revenue can be measured reliably. When the contract states that the buyer is entitled to return the purchased service under specific conditions, the Company can only recognize revenue when those specific conditions no longer exist and the buyer is not entitled to return the rendering service;
(b) It is possible to obtain economic benefits from the service provision transaction;
(c) The work volume finished on the date of making the accounting financial position statement can be determined;
(d) The costs incurred from the service provision transaction and the costs of its completion can be determined.

Interest

Interest is recognized on an accrual basis, are determined on the balance of cash in bank and the actual interest rate for each period.

Distributed dividends and profits

Dividends and distributed profits are recognized when the Company is entitled to receive dividends or profits from capital contributions. Dividends received in shares are only tracked for the number of additional shares, not the value of shares received.

4.18 Corporate income tax

Corporate income tax expenses for the year comprises only current income tax.

Current income tax

Current income tax is the tax amount is calculated on taxable income. Taxable income is different from accounting profit due to the adjustments of temporary differences between accounting and tax, non-deductible expenses as well as adjusted income are not taxed and losses be transferred.

Tax settlement of the Company will be assessed by the Tax Department. Due to the application of laws and regulations on taxes for different incurred transactions which can be explained in many different ways, tax payable presented in the financial statements can be immediately changed according to the decision of the tax authorities.

4.19 Segment reporting

A business segment is a distinguishable component that is engaged in providing a product or service and that has its own risks and returns which are different from those of other business segments.

A geographical segment a distinguishable component that is engaged in providing a product or services in a particular economic environment and that has its own risks and returns which are different from of segment operating in other economic environment.

4.20 Financial instrument

Financial assets

The classification of financial assets depends on the nature and purpose of the financial assets and is determined at the time of initial recognition. Financial assets of the Company include cash and cash equivalents, customer receivables and other receivables.

At the time of initial recognition, financial assets are determined at cost plus any costs directly transaction of such financial assets.

Financial liabilities

The classification of financial liabilities depends on the nature and purpose of the financial liabilities and is determined at the time of initial recognition. Financial liabilities of the Company include payable to suppliers, accrued expenses and other payables.

At the time of initial recognition, except for financial liabilities related to financial leasing and convertible bonds are recorded at cost allocation, other financial liabilities are determined at cost plus costs directly transaction of such financial liabilities.

Amortized cost is determined by the value of the initial recognition of financial liabilities minus principal repayments, plus or minus the cumulative amortization of interest calculated at the actual interest rate method of the difference between the value initially recognized and the maturity value, minus deductions (directly or through the use of a provision) by reducing the value or by irrevocable.

The real interest method is a method of calculating the amortized cost of one or a Company of financial liabilities and amortizing the interest income or interest expense in the relevant period. Real interest rate is the interest rate discounting the cash flows estimated to be paid or received in future during the expected lifetime of the financial instrument or a shorter, if necessary, return to the current book value net financial liabilities.

Owner's equity instruments

Owner's equity instruments are contracts that prove benefits remaining about asset of Company after deducting all of its obligation.

Offsetting of financial instruments

The financial assets and financial liabilities are offset and the net amount is presented on the financial position statement, and if only:

- The Company has the legal right to offset the values were recognized, and
- It intends to pay on a net basis or recognized assets and paid liabilities at the same time.

4.21 Related parties

The parties are related if having the ability to control or significant influence across the decision making of financial policies and operations. Parties are also considered to be related if they are subjected to common control or common significant influences.

The following individuals/ companies are considered as related parties:

Individuals / Company	**Location**	**Relationship**
An Sinh Hospital Joint Stock Company	Vietnam	Other related party
Orchids Trading Service Travel Company Limited	Vietnam	Other related party
Vietnam Pharmaceutical Corporation	Vietnam	Major Shareholder
The Board of Directors, the Board of Supervisors, the Board of General Directors		Key members

5. ADDITIONAL INFORMATION TO ITEMS IN THE INTERIM FINANCIAL POSITION STATEMENT

5.1 Cash and cash equivalents

		30/06/2026 VND	**01/01/2026** VND
Cash on hand – VND		2,016,997,931	2,611,008,748
Cash in bank – VND			
- Joint Stock Commercial Bank for Investment and Development of Vietnam		10,712,589,373	11,291,099,677
- Joint Stock Commercial Bank For Foreign Trade of Vietnam		2,247,700,014	581,592,097
- Vietnam Joint Stock Commercial Bank For Industry and Trade		2,808,047,324	4,396,201,878
- Other banks		34,727,521	33,670,608
Cash in bank – USD		526,001,523	1,184,759,471
Cash in bank – EUR		25,624,635	25,931,750
Cash equivalents	(*)	15,011,712,330	208,150,404,110
		33,383,400,651	**228,274,668,339**

(*) Cash equivalents are deposits with a term of 3 months or less deposited at commercial banks with interest rates according to each deposit contracts.

Detail of balance of cash in bank by foreign currency as at 30 June 2026, as follows:

	Foreign currency	Equivalent VND
Cash in bank		
- USD	20,010.71	526,001,523
- EUR	850.25	25,624,635

5.2 Financial investments

Financial investments of the Company include trading securities, held-to-maturity investments and investments in other entities, detail is as follows:

5.2.1 Trading securities

	30/06/2026			01/01/2026		
	Cost VND	Provision VND	Fair value VND	Cost VND	Provision VND	Fair value VND
Stock						
OPC Pharmaceutical JSC (a)	241,461,100	-	1,095,556,200	241,461,100	-	1,109,424,000
Pharmaceutical Packaging JSC	6,635,250,000	-	(*)	6,635,250,000	-	(*)
	6,876,711,100	**-**		**6,876,711,100**	**-**	

(a) The fair value of trading securities is determined according to the closing prices on 30 June 2026 and 31 December 2025 of the Ho Chi Minh Stock Exchange.

(*) At 30 June 2026 and 01 January 2026, the Company has not determined the fair value of these investments to disclose in the Notes to the financial statements, because there is no listed price on the market and Vietnamese accounting standards, the Vietnamese enterprise accounting regime. There is currently no guidance on how to calculate fair value and use valuation techniques. The fair value of these investments may differ from the carrying amount.

5.2.2 Held-to-maturity investments

	30/06/2026			01/01/2026		
	Cost VND	Recoverable amount VND	Provision VND	Cost VND	Recoverable amount VND	Provision VND
Short-term						
Time deposits	209,658,156,165	209,658,156,165	-	25,495,468,493	25,495,468,493	-
	209,658,156,165	**209,658,156,165**	**-**	**25,495,468,493**	**25,495,468,493**	**-**

The balance of short-term term deposits as at 30 June 2026 is deposits at commercial banks with a term of 6 months with interest rates according to each corresponding deposit contract.

5.2.3 Investments in other entities

	30/06/2026				01/01/2026			
	Ownership and voting	**Cost**	**Provision**	**Fair value**	**Ownership and voting**	**Cost**	**Provision**	**Fair value**
	%	VND	VND	VND	%	VND	VND	VND
Investments in other entities								
An Sinh Hospital Joint Stock Company (a)	18.34	18,518,960,000	-	(*)	18.34	18,518,960,000	-	(*)
Orchids Trading Service Travel Company Limited (b)	15.00	5,550,000,000	-	(*)	15.00	5,550,000,000	-	(*)
		24,068,960,000	**-**			**24,068,960,000**	**-**	

(a) An Sinh Hospital Joint Stock Company was established in Vietnam, operating under Business Registration Certificate No. 0302774433 dated 25 November 2002, the 18th amendment certificate dated 05 July 2022 issued by the Department of Planning and Investment of Ho Chi Minh City. An Sinh Hospital Joint Stock Company's Charter capital is VND 134,400,000,000. An Sinh Hospital Joint Stock Company's principal activities are operations of hospitals and clinics.

(b) Orchids Trading Service Travel Company Limited was established in Vietnam, operating under Business Registration Certificate No. 0312680625 dated 10 March 2014 issued by the Department of Planning and Investment of Ho Chi Minh City. Orchids Trading Service Travel Company Limited's Charter capital is VND 37,000,000,000. Orchids Trading Service Travel Company Limited's principal activities are short-term accommodation, restaurants and mobile catering services.

(*) At 30 June 2026 and 01 January 2026, the Company has not determined the fair value of these investments to disclose in the Notes to the financial statements, because there is no listed price on the market and Vietnamese accounting standards, the Vietnamese enterprise accounting regime. There is currently no guidance on how to calculate fair value and use valuation techniques. The fair value of these investments may differ from the carrying amount.

5.3 Short-term accounts receivables

	30/06/2026		01/01/2026	
	Cost	**Provision**	**Cost**	**Provision**
	VND	VND	VND	VND
Trade receivables – related parties				
An Sinh Hospital Joint Stock Company	179,702,094	-	287,295,698	-
Trade receivables – other parties				
Anh Dung Pharmaceuticals Trading Company Limited	14,023,467,414	-	9,940,581,596	-
Tan Tao Industrial Zone Branch (Zuellig)	9,385,514,766	(9,385,514,766)	9,385,514,766	(9,385,514,766)
Mekophar Chemical Pharmaceutical Joint-Stock Company (Hanoi Branch)	4,229,022,421	-	7,193,053,812	-
Other customers	27,053,127,772	(1,143,753,081)	31,108,282,429	(1,143,554,646)
	54,870,834,467	**(10,529,267,847)**	**57,914,728,301**	**(10,529,069,412)**

5.4 Short-term advances to suppliers

	30/06/2026	01/01/2026
	VND	VND
Advances to other suppliers		
Kim Nam Thinh Pharmaceutical Machine Manufacture Company Limited	1,257,780,000	1,309,000,000
Cozy Trading Company Limited	3,900,000,000	-
Viet Nam Applied Biology And Technical Joint Stock Company	1,357,700,000	-
Other suppliers	5,531,205,820	24,454,944,068
	12,046,685,820	**25,763,944,068**

5.5 Other short-term, long-term receivables

5.5.1 Other short-term receivables

	30/06/2026		01/01/2026	
	Amount	**Provision**	**Amount**	**Provision**
	VND	VND	VND	VND
Receivables – related parties				
An Sinh Hospital Joint Stock Company – dividends receivable	-	-	31,178,000,000	-
Receivables – other parties				
Advances	50,000,000	-	-	-
Pledge, collateral, deposit	10,500,000,000	-	10,500,000,000	-
Other receivables	486,577,783	(11,352,880)	1,136,071,316	(11,352,880)
	11,036,577,783	**(11,352,880)**	**42,814,071,316**	**(11,352,880)**

5.5.2 Other long-term receivables

	30/06/2026		01/01/2026	
	Amount	**Provision**	**Amount**	**Provision**
	VND	VND	VND	VND
Receivables – other parties				
Pledge, collateral, deposit	81,100,800	-	-	-
	81,100,800	**-**	**-**	**-**

These notes form an integral part of and should be read in conjunction with the accompanying financial statements.

5.6 Bad debts

	30/06/2026			01/01/2026		
	Cost	Recoverable amount	Provision	Cost	Recoverable amount	Provision
	VND	VND	VND	VND	VND	VND
Trade receivables						
Tan Tao Industrial Zone Branch (Zuellig)	9,385,514,766	-	(9,385,514,766)	9,385,514,766	-	(9,385,514,766)
National Phytopharma Joint-Stock Company - Tan Tao Industry Park Branch	762,038,533	-	(762,038,533)	762,038,533	-	(762,038,533)
Other customers	755,681,613	373,967,065	(381,714,548)	981,844,398	600,328,285	(381,516,113)
Other receivables						
Nipro Pharma Corporation	16,218,400	4,865,520	(11,352,880)	16,218,400	4,865,520	(11,352,880)
Advances to suppliers						
Kim Linh Phat Group Joint Stock Company	1,064,250,000	-	(1,064,250,000)	1,064,250,000	-	(1,064,250,000)
Other suppliers	200,391,797	-	(200,391,797)	202,355,297	-	(202,355,297)
	12,184,095,109	**378,832,585**	**(11,805,262,524)**	**12,412,221,394**	**605,193,805**	**(11,807,027,589)**

5.7 Inventories

	30/06/2026		01/01/2026	
	Cost	Provision	Cost	Provision
	VND	VND	VND	VND
Raw materials	484,927,589,976	-	486,200,092,655	-
Tools	2,034,891,732	-	1,868,215,875	-
Work-in-process	58,126,458,267	-	54,536,589,857	-
Finished goods	129,622,220,407	(30,342,893,861)	128,032,842,174	(30,342,893,861)
Goods	147,494,595	-	242,504,117	-
	674,858,654,977	**(30,342,893,861)**	**670,880,244,678**	**(30,342,893,861)**

5.8 Short-term, long-term deferred expenses

5.8.1 Short-term deferred expenses

	30/06/2026	01/01/2026
	VND	VND
Fire insurance expense	576,071,844	1,587,717,486
Office rental	1,051,956,200	-
Major repair of fixed assets, machinery spare part	595,000,000	-
Other short-term deferred expenses	1,682,490,436	2,125,130,201
	3,905,518,480	**3,712,847,687**

5.8.2 Long-term deferred expenses

	30/06/2026	01/01/2026
	VND	VND
Major repair of fixed assets, machinery spare part	1,718,054,554	1,991,697,449
	1,718,054,554	**1,991,697,449**

5.9 Increase, decrease of tangible fixed assets

	Building and structure VND	Machinery and equipment VND	Transportation VND	Office equipment VND	Total VND
HISTORICAL COST					
As at 01/01/2026	558,311,101,541	401,541,344,452	15,435,683,799	65,579,415,006	1,040,867,544,798
Purchase in period	-	13,976,709,800	-	40,000,000	14,016,709,800
Liquidation	-	(30,325,000)	-	-	(30,325,000)
As at 30/06/2026	**558,311,101,541**	**415,487,729,252**	**15,435,683,799**	**65,619,415,006**	**1,054,853,929,598**
ACCUMULATED DEPRECIATION					
As at 01/01/2026	122,778,977,070	254,413,623,954	13,795,082,392	55,358,166,010	446,345,849,426
Depreciation in period	7,166,170,992	9,979,288,764	210,624,874	1,398,261,233	18,754,345,863
Liquidation	-	(30,325,000)	-	-	(30,325,000)
As at 30/06/2026	**129,945,148,062**	**264,362,587,718**	**14,005,707,266**	**56,756,427,243**	**465,069,870,289**
NET BOOK VALUE					
As at 01/01/2026	435,532,124,471	147,127,720,498	1,640,601,407	10,221,248,996	594,521,695,372
As at 30/06/2026	**428,365,953,479**	**151,125,141,534**	**1,429,976,533**	**8,862,987,763**	**589,784,059,309**

The historical cost of fully depreciated tangible fixed assets but still in use as at 30 June 2026 are VND 184,520,690,256 (as at 31 December 2025: VND 183,402,555,893).

5.10 Increase, decrease of intangible fixed assets

	Land use right VND	Copyright, computer software VND	Total VND
HISTORICAL COST			
As at 01/01/2026	7,438,152,000	6,566,431,139	14,004,583,139
As at 30/06/2026	**7,438,152,000**	**6,566,431,139**	**14,004,583,139**
ACCUMULATED DEPRECIATION			
As at 01/01/2026	-	6,234,019,460	6,234,019,460
Depreciation in period	-	52,434,996	52,434,996
As at 30/06/2026	**-**	**6,286,454,456**	**6,286,454,456**
NET BOOK VALUE			
As at 01/01/2026	7,438,152,000	332,411,679	7,770,563,679
As at 30/06/2026	**7,438,152,000**	**279,976,683**	**7,718,128,683**

The historical cost of fully depreciated intangible fixed assets but still in use as at 30 June 2026 are VND 6,069,101,139 (as at 31 December 2024: VND 6,069,101,139)

5.11 Construction in progress

	01/01/2026 VND	Increase in period VND	Other transfers VND	30/06/2026 VND
Research, development and production project for biopharmaceuticals	-	9,553,733,333	-	9,553,733,333
Purchase of other assets	80,571,727	-	(80,571,727)	-
	80,571,727	**9,553,733,333**	**(80,571,727)**	**9,553,733,333**

5.12 Trade accounts payable

	30/06/2026 VND	01/01/2026 VND
Trade payables to other suppliers		
Toan Phuc Pharmaceutical Chemical Company Limited	5,743,900,000	24,700,170,527
Dong Nai Pharma Joint Stock Company	7,284,013,590	3,699,864,515
Sinopharm Weiqida Phar	11,881,272,000	-
Sinobright Pharmaceutical	4,459,157,040	11,421,241,000
Other suppliers	26,794,587,864	56,046,031,891
	56,162,930,494	**95,867,307,933**

5.13 Short-term advance from customers

	30/06/2026 VND	01/01/2026 VND
Advances from other customers		
Stem cell bank	11,097,048,690	12,038,265,690
T.N.T Pharmaceutical and Medical Equipment Joint Stock Company	18,616,700,492	18,616,700,492
Hamadu Pharma Company Limited	11,766,702,368	6,018,585,468
Other customers	12,265,661,277	9,468,996,425
	53,746,112,827	**46,142,548,075**

5.14 Dividends and profits payable

	30/06/2026 VND	01/01/2026 VND
Dividends payable to shareholders	12,634,110,500	-
	12,634,110,500	**-**

In period, the Company has distributed the profit according to the Resolution of the Annual General Meeting of Shareholders No. 34/NQ-DHDCD dated 18 April 2026 (see Notes 5.20).

5.15 Taxes and (receivables), payables to State budget

	01/01/2026	Transaction in period		30/06/2026
	Receivables VND	Payables VND	Paid/ Deducted VND	Receivables VND
VAT on domestic goods	-	20,727,374,735	(20,727,374,735)	-
VAT on import goods	-	4,865,900,831	(4,865,900,831)	-
Import tax	(105,626,642)	124,510,772	(20,643,233)	(1,759,103)
Corporate income tax	(1,557,130,085)	148,188,489	(7,037,039,273)	(8,445,980,869)
Personal income tax	-	1,457,909,203	(1,521,034,715)	(63,125,512)
Housing tax, land rental	(1,003,701)	9,600,000,000	(14,542,448,990)	(4,943,452,691)
	(1,663,760,428)	**36,923,884,030**	**(48,714,441,777)**	**(13,454,318,175)**

Value-added tax

The Company declares value-added tax by deduction method. VAT rates for domestic goods are non-taxable, 5%, 8% and 10%.

Corporate income tax

Corporate income tax ("CIT") payable in period is estimated as follows:

	From 01/01/2026 to 30/06/2026 VND	From 01/01/2025 to 30/06/2025 VND
Accounting profit before tax	**569,872,801**	**(29,484,039,585)**
Adjusted in accounting profit to determine taxable profit:		
Increase adjustments	-	167,409,248
Decrease adjustments	(14,126,719)	(9,809,959)
Assessable income	**555,746,082**	**(29,326,440,296)**
CIT rate	20%	20%
CIT payables	**111,149,216**	**-**
Adjustment for CIT in previous years	37,039,273	-
Current CIT expenses	**148,188,489**	**-**

The Company is obliged to pay tax at the normal rate of 20% of taxable income.

Other taxes

The Company declares and pays other taxes in accordance to current regulations.

5.16 Accrued expenses

	30/06/2026 VND	01/01/2026 VND
Accrued expenses - other individual, organization		
Accrued land rental expense	9,990,778,203	8,715,359,709
Other accrued expenses	341,464,364	598,335,409
	10,332,242,567	**9,313,695,118**

5.17 Other short-term payables

	30/06/2026 VND	01/01/2026 VND
Other payables - other individual, organization		
Trade union, social insurance, Party fees	105,708,540	106,195,740
Corporate income tax (Factory 24)	91,299,513	91,299,513
Soviet Union Antibiotic	118,181,818	118,181,818
Happy House Investment Joint Stock Company (*)	10,000,000,000	10,000,000,000
Other payables	756,013,247	818,975,258
	11,071,203,118	**11,134,652,329**

(*) Payment according to the progress of cooperation with Happy House Company to implement a social housing project under the Investment Cooperation Contract No. 01/2018/HDHT dated 08 August 2018.

5.18 Bonus and welfare funds

	01/01/2026 VND	Increase in period VND	Paid in period VND	30/06/2026 VND
Bonus fund	1,980,284,788	344,108,099	(1,734,900,000)	589,492,887
Welfare fund	3,711,279,102	344,108,098	(21,959,800)	4,033,427,400
	5,691,563,890	**688,216,197**	**(1,756,859,800)**	**4,622,920,287**

5.19 Long-term unrealized revenue

	30/06/2026 VND	01/01/2026 VND
MekoStem unrealized revenue	206,449,919,991	201,863,579,435
Finished goods unrealized revenue	-	25,523,810
	206,449,919,991	**201,889,103,245**

5.20 Owner's equity

5.20.1 Owner's equity movements

	Owners' invested capital VND	Share premium VND	Treasury shares VND	Investment and development fund VND	Retained earnings VND	Total VND
As at 01/01/2025	255,458,670,000	409,789,114,458	(14,487,151,158)	578,599,664,283	55,323,709,580	1,284,684,007,163
Profit in period	-	-	-	-	(29,484,039,585)	(29,484,039,585)
Deduction for Investment and development fund	-	-	-	3,230,180,022	(3,230,180,022)	-
Deduction for Bonus and welfare funds	-	-	-	-	(6,460,360,043)	(6,460,360,043)
Dividends distribution	-	-	-	-	(12,634,110,500)	(12,634,110,500)
Remuneration for the Board of Directors	-	-	-	-	(408,000,000)	(408,000,000)
As at 30/06/2025	**255,458,670,000**	**409,789,114,458**	**(14,487,151,158)**	**581,829,844,305**	**3,107,019,430**	**1,235,697,497,035**
As at 01/07/2025	255,458,670,000	409,789,114,458	(14,487,151,158)	581,829,844,305	3,107,019,430	1,235,697,497,035
Profit in period	-	-	-	-	33,785,390,819	33,785,390,819
As at 31/12/2025	**255,458,670,000**	**409,789,114,458**	**(14,487,151,158)**	**581,829,844,305**	**36,892,410,249**	**1,269,482,887,854**
As at 01/01/2026	255,458,670,000	409,789,114,458	(14,487,151,158)	581,829,844,305	36,892,410,249	1,269,482,887,854
Profit in period	-	-	-	-	421,684,312	421,684,312
Deduction for Investment and development fund	-	-	-	344,108,099	(344,108,099)	-
Deduction for Bonus and welfare funds	-	-	-	-	(688,216,197)	(688,216,197)
Dividends distribution	-	-	-	-	(12,634,110,500)	(12,634,110,500)
As at 30/06/2026	**255,458,670,000**	**409,789,114,458**	**(14,487,151,158)**	**582,173,952,404**	**23,647,659,765**	**1,256,582,245,469**

5.20.2 Detail of owner's invested equity

According to the Company's the Business Registration Certificate (amended), the Charter capital of the Company is VND 255,458,670,000. As at 30 June 2026, the Company's Charter capital was fully contributed as follows:

	30/06/2026			01/01/2026		
	Shares	Value VND	Rate %	Shares	Value VND	Rate %
Huynh Thi Lan	6,223,981	62,239,810,000	24.36	6,223,981	62,239,810,000	24.36
Vietnam Pharmaceutical Corporation	4,657,435	46,574,350,000	18.23	4,657,435	46,574,350,000	18.23
Other shareholders	14,664,451	146,644,510,000	57.41	14,664,451	146,644,510,000	57.41
	25,545,867	**255,458,670,000**	**100.00**	**25,545,867**	**255,458,670,000**	**100.00**

5.20.3 Shares

	30/06/2026	01/01/2026
	Share	Share
Number of issued registered shares	25,545,867	25,545,867
Number of shares sold to the public	25,545,867	25,545,867
Common shares	*25,545,867*	*25,545,867*
Preferred shares	-	-
Number of repurchased shares	277,646	277,646
Common shares	*277,646*	*277,646*
Preferred shares	-	-
Number of shares in circulation	25,268,221	25,268,221
Common shares	*25,268,221*	*25,268,221*
Preferred shares	-	-

Par value of shares in circulation: VND 10,000/ share.

5.20.4 Profit distribution

In period, the Company distributed dividends according to the Resolution of the Annual General Meeting of Shareholders No. 34/NQ-DHDCD dated 18 April 2026 with the value of 5% par value.

In addition, the Company distributed profit of 2025 according to the Resolution of the Annual General Meeting of Shareholders No. 34/NQ-DHDCD dated 18 April 2026 as follows:

		VND
- Deduct 8% from retained earnings of 2025 for Investment and development fund	:	344,108,099
- Deduct 16% from retained earnings of 2025 for Bonus and welfare funds	:	688,216,197

5.21 Off-financial position statement items

Foreign currency

	30/06/2026	01/01/2026
	Foreign currency	Foreign currency
US Dollar (USD)	20,010.71	45,433.12
Euro (EUR)	850.25	854.46

6. ADDITIONAL INFORMATION FOR ITEMS SHOWN IN THE INTERIM INCOME STATEMENT

6.1 Revenues from sale of goods and rendering of services

6.1.1 Net revenues

	From 01/01/2026 to 30/06/2026	From 01/01/2025 to 30/06/2025
	VND	VND
Revenue from sale of goods	106,335,238	205,009,513
Revenue from sale of finished goods	376,028,159,440	378,507,033,566
Revenue from sale of materials	281,519,717	2,420,268,423
Revenue from rental	5,565,000,000	5,565,000,000
Revenue from stem cell bank service	29,849,579,444	34,242,805,671
Sale deductions:		
- Sales returns	(41,497,128)	(92,845,934)
Net revenue	**411,789,096,711**	**420,847,271,239**

6.1.2 Sales of goods and rendering of services to related parties

Transaction of sales of goods and rendering of services to related parties are follows:

	From 01/01/2026 to 30/06/2026 VND	From 01/01/2025 to 30/06/2025 VND
An Sinh Hospital Joint Stock Company	5,363,689,440	5,157,253,090
Orchids Trading Service Travel Company Limited	1,425,000,000	1,425,000,000
	6,788,689,440	**6,582,253,090**

6.2 Cost of sales

	From 01/01/2026 to 30/06/2026 VND	From 01/01/2025 to 30/06/2025 VND
Cost of goods sold	101,752,379	184,661,914
Cost of finished goods sold	284,016,745,692	292,562,543,166
Cost of materials sold	-	1,563,295,673
Cost of stem cell bank service	9,773,964,979	10,501,445,530
	293,892,463,050	**304,811,946,283**

6.3 Financial income

	From 01/01/2026 to 30/06/2026 VND	From 01/01/2025 to 30/06/2025 VND
Interest from deposit	6,730,598,453	2,040,427,659
Dividends, distributed profit	-	540,000,000
Foreign exchange gain	119,305,804	262,530,421
	6,849,904,257	**2,842,958,080**

6.4 Financial expenses

	From 01/01/2026 to 30/06/2026 VND	From 01/01/2025 to 30/06/2025 VND
Provision for investment in subsidiary	-	23,506,143,017
Foreign exchange loss	814,372,540	1,654,719,131
Foreign exchange loss due to the revaluation of monetary items denominated in foreign currencies	110,688,441	158,649,585
	925,060,981	**25,319,511,733**

6.5 Selling expenses

	From 01/01/2026 to 30/06/2026 VND	From 01/01/2025 to 30/06/2025 VND
Labor expenses	11,318,470,481	11,574,771,576
Depreciation expenses	216,063,784	165,798,630
Marketing expenses	20,817,179,180	18,194,327,456
Transportation expenses	843,871,171	1,116,943,333
Service expense	20,101,755,974	25,147,055,054
Other selling expenses	224,184,000	163,920,640
	53,521,524,590	**56,362,816,689**

NOTES TO THE INTERIM FINANCIAL STATEMENTS

For the six-month period ended 30 June 2026

These notes form an integral part of and should be read in conjunction with the accompanying financial statements.

6.6 General and administration expenses

	From 01/01/2026 to 30/06/2026 VND	From 01/01/2025 to 30/06/2025 VND
Labor expenses	24,328,645,428	23,021,902,640
Tools and equipment expenses	6,624,588,914	10,361,601,356
Depreciation expenses	9,442,869,459	1,808,093,028
Tax and fees	10,900,221,290	12,257,228,621
Provision expenses	(1,765,065)	133,253,389
Service expenses	4,501,806,418	2,102,990,615
Other general and administration expenses	13,793,715,879	17,304,924,604
	69,590,082,323	**66,989,994,253**

6.7 Other incomes

	From 01/01/2026 to 30/06/2026 VND	From 01/01/2025 to 30/06/2025 VND
Gain from disposal of fixed assets	-	22,727,273
Other income	8,323,285	336,950,883
	8,323,285	**359,678,156**

6.8 Other expenses

	From 01/01/2026 to 30/06/2026 VND	From 01/01/2025 to 30/06/2025 VND
Administrative fines	16,320,508	-
Other expenses	132,000,000	49,678,102
	148,320,508	**49,678,102**

6.9 Basic earnings per share

The calculation of basic earnings per share attributable to shareholders holding common shares of the Company are made on the basis of the following data:

	From 01/01/2026 to 30/06/2026 VND	From 01/01/2025 to 30/06/2025 VND
Profit for the year attributable to shareholders holding common shares of the Company	**421,684,312**	**(29,484,039,585)**
Deduction: bonus and welfare funds	-	-
Profit to calculate EPS	**421,684,312**	**(29,484,039,585)**
Outstanding common shares on average during the year (share)	25,268,221	25,268,221
Earnings per share (VND/share)	**17**	**(1,167)**

(*) The Company has not yet planned to distribute bonus and welfare funds from profits after tax of 2026 at the time of preparing the financial statements for the six-month accounting period ended 30 June 2026.

6.10 Production and business costs by element

	From 01/01/2026 to 30/06/2026 VND	From 01/01/2025 to 30/06/2025 VND
Material expenses	260,669,400,608	286,089,667,382
Labor expenses	59,609,753,531	60,443,397,687
Depreciation expenses	18,806,780,859	4,620,733,244
External service expenses	36,790,875,688	37,959,108,922
Other expenses	48,104,780,297	49,254,114,078
	423,981,590,983	**438,367,021,313**

7. FINANCIAL INSTRUMENTS

The Company has financial assets such as trade receivables and other receivables, cash and short-term deposits that occur directly from the operations of the Company. Financial liabilities of the Company mainly include loans, payables to suppliers and other payables. The main purpose of these financial liabilities is to mobilize financial resources to serve the activities of the Company.

The Company has market risk, credit risk and liquidity risk.

Operational risk management is indispensable operations for the entire operations of the Company. The Company has developed control system to ensure balance between the extent reasonable costs incurred when risk and risk management costs. The Company has not implemented measures to prevent this risk due to lack of a market to purchase financial instruments.

The Board of General Directors considered and uniformly applies policies to manage each of these risks are summarized below:

i. Market risk

Market risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate because of changes in market prices. Market risk has four types of risk: interest rate risk, currency risk, goods price risk and other price risk, such as equity price risk.

Interest rate risk

Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. Market risk for changes in interest rates of the Company primarily relating to cash, short term deposits, and loans of the Company.

The Company managing interest rate risk by analyzing the competitive situation in the market to acquire beneficial interest for the purposes of the Company and remain within the limits of their risk management.

Foreign currency risk

Foreign currency risk is the risk that the fair value of the future cash flows of a financial instrument will fluctuate because of changes in exchange rates. The Company bears the risk of changes in exchange rates, which are directly related to the business operations of the Company.

Stock price risk

The shares held by the Company are affected by market risks arising from uncertainty about the future value of the investment shares. The company manages stock price risk by setting investment limits. The Board of General Directors also reviews and approves investment decisions in shares. The Company considers the share price risk to be negligible.

ii. Credit risk

Credit risk is the risk that one party of a financial instrument or contract not performing its obligations, resulting in financial losses. The Company has credit risk from its operating activities (primarily for trade receivables account), and from its financial activities, including bank deposits and other financial instruments.

Trade receivables

The Company regularly monitors the receivables, which is not yet collected. For big customers, the Company considered the decline in the credit quality of each customer at the reporting date. The Company seeks the way to remained the tight control of the receivables and arranging credit control staff to minimize credit risk. On this basis and the trade receivables of the Company related to many different customers, credit risk is not significantly concentrated in a certain customer.

Cash in bank

The Company mainly maintains deposit balances at banks, which is well known in Vietnam. Credit risk of the deposit balances at banks is managed by the treasury department of the Company under the policies of the Company. The maximum credit risk of the Company for the items on the financial position statement at the end of the financial year is the value book as presented in Note 5.1. The Company found that the level of concentration of credit risk on bank deposits is low.

iii. Liquidity risk

Liquidity risk is the risk that the Company will encounter difficulties in implementing their financial obligations due to lack of funds. Liquidity risk of the Company mainly arising from financial assets and financial liabilities with maturity mismatches.

The Company minimizes the liquidity risk by maintaining an amount of cash and cash equivalents and bank loans at a level that the Board of General Director supposes it is sufficient to meet the Company's operations and minimize the risks due to the volatility of cash flows.

The table below summarizes the maturity of the financial liabilities of the Company based on expected payments on undiscounted basic contracts:

	Less than 1 year VND	From 1 to 5 years VND	Total VND
As at 30/06/2026			
Trade payables	56,162,930,494	-	56,162,930,494
Accrued expenses	10,332,242,567	-	10,332,242,567
Other payables	11,000,535,118	-	11,000,535,118
	77,495,708,179	**-**	**77,495,708,179**
As at 01/01/2026			
Trade payables	95,867,307,933	-	95,867,307,933
Accrued expenses	9,313,695,118	-	9,313,695,118
Other payables	11,063,277,529	-	11,063,277,529
	116,244,280,580	**-**	**116,244,280,580**

The Company considered that the level of concentration risk to the repayment is low. The Company has sufficient access to the necessary capital.

Security assets

The Company does not hold the security assets of third parties as at 30 June 2026 and 01 January 2026.

iv. Fair value

(1) Compare fair value and book value

	Book value		**Fair value (*)**	
	30/06/2026 VND	**01/01/2026** VND	**30/06/2026** VND	**01/01/2026** VND
Financial assets				
Held-to-maturity investments	209,655,484,932	25,495,468,493	209,655,484,932	25,495,468,493
Trade receivables	54,870,834,467	57,914,728,301	44,341,566,620	47,385,658,889
Other receivables	11,067,678,583	42,814,071,316	11,056,325,703	42,802,718,436
Financial assets available for sale				
Short-term financial investments	6,876,711,100	6,876,711,100	6,876,711,100	6,876,711,100
Long-term financial investments	24,068,960,000	24,068,960,000	24,068,960,000	24,068,960,000
Cash and cash equivalents	33,386,071,884	228,274,668,339	33,386,071,884	228,274,668,339
	339,925,740,966	**385,444,607,549**	**329,385,120,239**	**374,904,185,257**
Financial liabilities				
Financial liabilities are determined according to the distribution value				
Trade payables	56,162,930,494	95,867,307,933	56,162,930,494	95,867,307,933
Accrued expenses	10,332,242,567	9,313,695,118	10,332,242,567	9,313,695,118
Other payables	11,000,535,118	11,063,277,529	11,000,535,118	11,063,277,529
	77,495,708,179	**116,244,280,580**	**77,495,708,179**	**116,244,280,580**

(*) The Company has not revaluated its financial assets and financial liabilities at their fair values as at 30 June 2026 and 01 January 2026. However, the Board of General Directors believes that the fair value of these financial assets and liabilities is not significantly different from their carrying amounts as at the financial position statement date.

(2) Basis of determining fair value

Accounts receivable and other receivables

The fair value of accounts receivables and other receivables, excluding accounts receivable and payable under the scheduled progress of construction contracts, is estimated based on the present value of cash flows future, discounted at market interest rates at the report date. The fair value of these instruments is determined only intended disclosures.

Non-derivative financial liabilities

The fair value determined only intended disclosures, is calculated by discounting the value of loans and its interest by market interest at the financial position statement date.

8. OTHER INFORMATION

8.1 Transactions and balances with related parties

The related parties with the Company include key management members, the individuals involved with key members and other related parties.

8.1.1 Transactions and balances with key members, the individuals involved with key members

Remuneration paid to key management members during the period was as follow:

	From 01/01/2026 to 30/06/2026 VND	From 01/01/2025 to 30/06/2025 VND
Salary and bonus		
Mr. Le Anh Phuong	837,491,819	784,160,888
Ms. Huynh Thi Lan	1,278,152,338	1,195,563,745
Ms. Dang Thi Kim Lan	416,491,651	687,575,486
Ms. Phan Thi Lan Huong	1,527,044,474	1,312,112,673
Mr. Satoshi Kawamura *(former member of the Board of Directors)*	-	48,000,000
Ms. Nguyen Thi Quynh Anh *(former member of the Board of Directors)*	-	315,220,401
Ms. Lu Thi Khanh Tran *(former member of the Board of Supervisors)*	-	48,000,000
Ms. Nguyen Thi Hang	72,000,000	24,000,000
	4,131,180,282	**4,414,633,193**

8.1.2 Transactions and balances with other related parties

Significant transactions with related parties in period are as follows:

Related parties	Transaction	From 01/01/2026 to 30/06/2026 VND	From 01/01/2025 to 30/06/2025 VND
An Sinh Hospital Joint Stock Company			
	Sales and services rendered	5,363,689,440	5,157,253,090
Orchids Trading Service Travel Company Limited			
	Sales and services rendered	1,425,000,000	1,425,000,000

Balance with related parties are as follows:

Related parties	Transaction	30/06/2026 VND	01/01/2026 VND
An Sinh Hospital Joint Stock Company			
	Trade receivables	179,702,094	287,295,698
	Other receivables	-	31,178,000,000

8.2 Segment information

8.2.1 Segment information by operating activities

Segment income statement operating activities for the six-month period ended 30 June 2026:

Items	Net revenue VND	Cost VND	Gross profit VND
Goods	106,335,238	101,752,379	4,582,859
Finished goods	375,986,662,312	284,016,745,692	91,969,916,620
Materials	281,519,717	-	281,519,717
Rental	5,565,000,000	-	5,565,000,000
Stem cell bank service	29,849,579,444	9,773,964,979	20,075,614,465
	411,789,096,711	**293,892,463,050**	**117,896,633,661**

Segment income statement operating activities for the six-month period ended 30 June 2025:

Items	Net revenue VND	Cost VND	Gross profit VND
Goods	205,009,513	184,661,914	20,347,599
Finished goods	378,414,187,632	292,562,543,166	85,851,644,466
Materials	2,420,268,423	1,563,295,673	856,972,750
Rental	5,565,000,000	-	5,565,000,000
Stem cell bank service	34,242,805,671	10,501,445,530	23,741,360,141
	420,847,271,239	**304,811,946,283**	**116,035,324,956**

8.2.2 Segment information by geographical area

The Company does not present segment information by geographical area, because all activities take place in the only geographical area, which is Vietnam.

8.3 Events subsequent to the financial position statement date

There have been no significant events occurring after the financial position statement date (30 June 2026) to the date of this report, which would require adjustments or disclosures to be made in the interim financial statements.

M.S.D.N: 0302533156 - C.T.C.P.
CÔNG TY CỔ PHẦN HÓA-DƯỢC PHẨM MEKOPHAR
THÀNH PHỐ HỒ CHÍ MINH

LE THI THU HUONG	PHAN ANH TAI	PHAN THI LAN HUONG
Preparer	Chief Accountant	General Director
		Legal representative
		Approved, 14 August 2026

Digitally signed by CÔNG TY CỔ PHẦN HÓA - DƯỢC PHẨM MEKOPHAR
Date: 2026.08.14 16:16:54 +07'00'